Recent studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating promising results in treating excess mass and type 2 diabetes. Initial information suggest a distinct mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/